Our Team

We are an interdisciplinary team of physicians and scientists with backgrounds in medicine, immunology, cancer, autoimmunity, synthetic biology, bioinformatics, and machine learning. Our culture is positive, collaborative, innovative, and fast-paced. What drives us is the unique opportunity to create advanced T cell therapies that could transform patient care.

Zinaida Good

Assistant Professor of Medicine

Division of Immunology and Rheumatology

Center for Biomedical Informatics Research

Director, Cancer Cell Therapy Data Hub

Dr. Good is an Assistant Professor in the Division of Immunology and Rheumatology and the Center for Biomedical Informatics Research within the Department of Medicine at Stanford University, the Director of the Cancer Cell Therapy Data Hub at the Stanford Center for Cancer Cell Therapy [.html], a member of Stanford Bio-X [https://biox.stanford.edu/], and a Parker Institute for Cancer Immunotherapy Investigator. Her research program is focused on understanding and enhancing engineered T cell immunotherapies for cancer and immune-mediated diseases through innovative computational approaches and systems immunology.

During her postdoctoral training with Drs. Crystal Mackall and Sylvia Plevritis, where she performed fate mapping studies to identify features of optimal CAR T cells in large B cell lymphoma (LBCL) and diffuse midline glioma (DMG), and discovered the role of CAR T regulatory cells in resistance to CD19-CAR in LBCL. She earned her Ph.D. in Computational & Systems Immunology from Stanford University, where she trained with Drs. Garry Nolan and Sean Bendall and developed methods to build and leverage lymphocyte differentiation trajectories in health and cancer. Dr. Good's background in experimental immunology and oncology combines two years of experience in Discovery Oncology at Genentech with B.S. and M.S. degrees in Microbiology & Immunology from the University of British Columbia, where she investigated mechanisms of T cell memory with Dr. Michael Gold.

Dr. Good’s work includes 4 first-author papers (Nature Medicine 2018 & 2022, Nature Biotechnology 2019, Trends in Immunology 2019), 17 co-authored papers (including Nature 2019, 2022, 2024, Science 2021, Nature Methods 2016, 2022, and NEJM 2024), and 2 patent applications. Her research is supported by the NIH Pathway to Independence Award, Parker Institute for Cancer Immunotherapy Bridge Fellowship, American Cancer Society Institutional Research Grant, and Parker Institute for Cancer Immunotherapy Innovation Challenge Grant. Dr. Good has been named an Arthur & Sandra Irving Cancer Immunology Fellow in 2022 and an AACR-Woman in Cancer Research Scholar in 2024.

Links:

Biography